Becton, Dickinson and Company BDX Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Segment Other Operating Expense (Income), net as a Percent of Revenues by Business | ||||||
| BioPharma Systems | 0%— | 0%— | —— | —— | 0%— | |
| Connected Care | 0.3%0.0pp | 0.3%— | —— | —— | 0.2%-0.4pp | |
| Interventional | 0%— | 0%— | —— | —— | 0%— | |
| Medical Essentials | 0%— | 0%— | —— | —— | 0%— | |
| Revenue by Business | ||||||
| BioPharma Systems | $590M+37.5% | $429M— | —— | —— | $575M+37.6% | |
| Connected Care | $1.12B-1.0% | $1.13B— | —— | —— | $1.07B-0.5% | |
| Interventional | $1.36B+2.0% | $1.33B-2.8% | $1.37B+3.0% | $1.33B+5.1% | $1.26B+0.6% | |
| Medical Essentials | $1.65B+3.3% | $1.6B— | —— | —— | $1.57B-0.8% | |
| Other Operating Income by Business | ||||||
| BioPharma Systems | $0— | $0— | —— | —— | $0— | |
| Connected Care | -$3M0.0% | -$3M— | —— | —— | -$2M+66.7% | |
| Interventional | $0— | $0— | —— | —— | $0— | |
| Medical Essentials | $0— | $0— | —— | —— | $0— | |
| Segment Selling and Administrative as a Percent of Revenues by Business | ||||||
| BioPharma Systems | 5.4%-1.2pp | 6.6%— | —— | —— | 4.8%-2.0pp | |
| Connected Care | 17%+0.1pp | 16.9%— | —— | —— | 15.1%-0.6pp | |
| Interventional | 20.4%+0.7pp | 19.7%— | —— | —— | 18.6%-0.3pp | |
| Medical Essentials | 11.2%-0.1pp | 11.3%— | —— | —— | 10.4%0.0pp | |
| Operating Income (Loss) by Business | ||||||
| BioPharma Systems | $225M+60.7% | $140M— | —— | —— | $224M+58.9% | |
| Connected Care | $347M-1.4% | $352M— | —— | —— | $353M+5.1% | |
| Interventional | $579M+3.2% | $561M— | —— | —— | $565M+0.7% | |
| Medical Essentials | $574M+0.9% | $569M— | —— | —— | $617M+1.6% | |
| Segment Cost of Products and Services Sold as a Percent of Revenues by Business | ||||||
| BioPharma Systems | 53.6%-3.0pp | 56.6%— | —— | —— | 53.2%-2.2pp | |
| Connected Care | 43.7%-0.6pp | 44.3%— | —— | —— | 44.8%-0.2pp | |
| Interventional | 31.6%-1.9pp | 33.5%— | —— | —— | 31.7%-0.4pp | |
| Medical Essentials | 50.7%+0.6pp | 50.1%— | —— | —— | 47%-1.5pp | |
| Segment Research and Development as a Percent of Revenues by Business | ||||||
| BioPharma Systems | 2.8%-1.3pp | 4.1%— | —— | —— | 3.1%-1.0pp | |
| Connected Care | 8.1%+0.6pp | 7.5%— | —— | —— | 6.9%-0.5pp | |
| Interventional | 5.3%+0.6pp | 4.7%— | —— | —— | 5%+0.6pp | |
| Medical Essentials | 3.2%+0.3pp | 2.9%— | —— | —— | 3.1%+0.3pp | |
| Segment Operating Income (Loss) as a Percent of Revenues by Business | ||||||
| BioPharma Systems | 38.1%+5.5pp | 32.6%— | —— | —— | 38.9%+5.2pp | |
| Connected Care | 31%-0.1pp | 31.1%— | —— | —— | 33%+1.7pp | |
| Interventional | 42.7%+0.6pp | 42.1%— | —— | —— | 44.7%+0.1pp | |
| Medical Essentials | 34.8%-0.8pp | 35.6%— | —— | —— | 39.3%+1.0pp | |
| Selling and administrative expense by Business | ||||||
| BioPharma Systems | $32M+10.3% | $29M— | —— | —— | $28M-3.4% | |
| Connected Care | $190M-0.5% | $191M— | —— | —— | $161M-4.2% | |
| Interventional | $277M+5.7% | $262M— | —— | —— | $236M-0.4% | |
| Medical Essentials | $185M+2.8% | $180M— | —— | —— | $164M-0.6% | |
| Cost of products sold by Business | ||||||
| BioPharma Systems | $316M+30.0% | $243M— | —— | —— | $306M+31.9% | |
| Connected Care | $490M-2.2% | $501M— | —— | —— | $478M-1.0% | |
| Interventional | $429M-3.6% | $445M— | —— | —— | $401M-0.7% | |
| Medical Essentials | $835M+4.4% | $800M— | —— | —— | $743M-3.5% | |
| Research and development expense by Business | ||||||
| BioPharma Systems | $17M-5.6% | $18M— | —— | —— | $18M+5.9% | |
| Connected Care | $90M+5.9% | $85M— | —— | —— | $74M-7.5% | |
| Interventional | $72M+14.3% | $63M— | —— | —— | $63M+12.5% | |
| Medical Essentials | $53M+12.8% | $47M— | —— | —— | $48M+9.1% | |
| D&A by Business | ||||||
| BioPharma Systems | $27M-20.6% | $34M— | —— | —— | $32M+3.2% | |
| Connected Care | $194M0.0% | $194M— | —— | —— | $199M+2.6% | |
| Interventional | $192M-2.5% | $197M— | —— | —— | $198M-1.0% | |
| Medical Essentials | $147M+4.3% | $141M— | —— | —— | $136M+0.7% | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| BioPharma Systems | $0— | $0— | —— | —— | —— | |
| Connected Care | -$1M0.0% | -$1M— | —— | —— | —— | |
| Interventional | $13M+533% | -$3M+62.5% | -$8M+88.4% | -$69M-188% | -$24M-136% | |
| Medical Essentials | $6M+250% | -$4M— | —— | —— | —— | |
| Goodwill by Business | ||||||
| BioPharma Systems | $96M0.0% | $96M0.0% | $96M— | —— | —— | |
| Connected Care | $6.1B0.0% | $6.09B0.0% | $6.09B— | —— | —— | |
| Interventional | $12.76B-0.1% | $12.77B0.0% | $12.76B+0.1% | $12.76B+0.5% | $12.69B+0.2% | |
| Medical Essentials | $7.01B-0.1% | $7.02B+0.1% | $7.01B— | —— | —— | |
| Revenue, remaining performance obligation, amount by Product | ||||||
| Consumables | $2B-16.7% | $2.4B+4.3% | $2.3B0.0% | $2.3B+4.5% | $2.2B+10.0% | |
| Products and/or Services | $2.3B-8.0% | $2.5B-10.7% | $2.8B+12.0% | $2.5B+4.2% | $2.4B+4.3% | |
| Revenue by Geography | ||||||
| International | $1.8B-14.1% | $2.09B-15.2% | $2.47B+6.0% | $2.33B+36.6% | $1.7B-18.4% | |
| UNITED STATES | $2.92B-7.7% | $3.16B-7.7% | $3.42B+7.5% | $3.18B+14.6% | $2.78B-9.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Becton, Dickinson and Company break its business down?
- Becton, Dickinson and Company (BDX) reports segment other operating expense (income), net as a percent of revenues by business across 5 parts — BioPharma Systems, Connected Care, Interventional, Medical Essentials and Medical. Each is extracted from the segment footnotes and tracked over time.
- Where does Becton, Dickinson and Company's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Becton, Dickinson and Company's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
